Oculogica

Oculogica is a commercial-stage medical device company that has successfully brought an objective, software-driven diagnostic for concussion to market. Its flagship product, the EyeBOX, is an FDA-cleared device that quantifies eye movement abnormalities to aid in concussion diagnosis, addressing a critical need for tools beyond subjective assessments. The company targets a broad market including sports clinics, neurology practices, and military medicine, leveraging a reimbursement-ready business model. With 16 peer-reviewed studies supporting its technology, Oculogica is positioned as a leader in the objective assessment of traumatic brain injury.

Proprietary eye-tracking hardware and software algorithm that measures cranial nerve function via eye movement abnormalities to objectively assess neurological health, specifically for concussion. It is baseline-free and non-invasive.

Oculogica competes in the objective concussion assessment space, which includes legacy computerized neurocognitive tests (e.g., ImPACT, which requires a baseline), emerging blood biomarker tests (e.g., Abbott's Banyan BTI, Quidel's FDA-cleared test), and other digital/balance technologies. EyeBOX's differentiation is its FDA clearance for diagnosis (not just screening), its baseline-free nature, and its focus on the direct physiological pathway of cranial nerve function.